Prostate Cancer News on BioPortfolio

FDA Approves First Treatment for Nonmetastatic CRPC

The US Food and Drug Administration FDA has approved the oral agent apalutamide Erleada for the treatment of nonmetastatic castrationresistant prostate cancer. The oral androgenreceptor inhibitor is the first FDAapproved treatment for patients with nonmeta...

Dad Can Pass on Ovarian Cancer Genes Too

FRIDAY Feb. 16 2018 A gene mutation that's passed down from a father is associated with earlier onset of ovarian cancer in daughters and prostate cancer in the father and his sons a new study suggests.Previous research had shown that sisters...

News Apalutamide shows efficacy in prostate cancer

The androgen receptor inhibitor apalutamide significantly improves metastasisfree survival in patients with nonmetastatic castrationresistant prostate cancer according to a recent study.

J&J gets quick approval for new nextgen prostate cancer drug

The FDA has approved Johnson & Johnsons next generation prostate cancer drug apalutamide in an early but tough to treat form of prostate cancer that has not spread.Approval of the drug which J&J will market under the brand name Erleada...